Daiichi Sankyo Company, Limited 4568
TSE · Japan · Health Technology
¥2,740.50-59.50 (-2.13%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Daiichi Sankyo Company (TSE:4568) is back in focus after it voluntarily withdrew a U.S. accelerated approval filing for ifinatamab deruxtecan, while larger Phase 3 trials for the drug continue across several cancer indications. The latest ifinatamab setback has followed a weaker run for Daiichi Sankyo Company, with the share price at ¥2,800 and the year-to-date share price return down 20.68%, while the 1-year total shareholder return has fallen 14.53% and the 5-year total shareholder return...
Daiichi Sankyo Co Ltd (DSKYF) recently announced a total dividend of $0.31 per share, with the ex-dividend date set for 2026-09-29. This amount consists entirely of a $0.31 per share cash dividend. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after platinum-based chemotherapy. Following FDA discussions, the partners said the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements. The investment […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.